BUZZ-Ideaya Biosciences falls as quarterly loss widens

Shares of drug developer Ideaya Biosciences IDYA.O fall 4.6% to $20.94

Co reports Q4 net loss of $130.3 million compared with net loss of $34.0 million a year ago

Collaboration revenue for the quarter was $7 million compared to $3.9 million a year earlier

Co received milestone payment from GSK GSK.L

As of December 31, co had cash, cash equivalents and marketable securities of about $1.1 billion, compared to $632.6 million a year earlier

Separately, co entered into an additional clinical study collaboration and supply agreement with Gilead Sciences GILD.O to test IDYA's experimental drug, IDE397, in combination with GILD's trodelvy to treat a type of lung cancer

In the last 12 months, IDYA has fallen ~53%